Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing

Xinchang Chen, a Guiqing He, b Siran Lin, a Shiyong Wang, a Feng Sun, a Jiazhen Chen, a Wenhong Zhang, c,d,e

aDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China
bDepartment of Infectious Diseases, Wenzhou Central Hospital, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou, China
cState Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, China
dNational Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
eKey Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China

Xinchang Chen and Guiqing He contributed equally to this work. Author order was determined both alphabetically and in order of increasing seniority.

Jiazhen Chen and Wenhong Zhang contributed equally to this work. Author order was determined both alphabetically and in order of increasing seniority.

ABSTRACT  The cure rate of multidrug-resistant tuberculosis (MDR-TB) is relatively low in China. The reasons for the treatment failure and within-host evolution during treatment have not been sufficiently studied. All MDR-TB patients receiving standard treatment from January 2014 to September 2016 at a designated TB Hospital in Zhejiang Province were retrospectively included and grouped according to their known treatment outcome. Clinical information was collected. Baseline strains of all patients and serial strains of treatment-failure patients were revived. Drug susceptibility tests (DSTs) of 14 drugs and single nucleotide polymorphism (SNP) analysis based on whole-genome sequencing (WGS) were performed. The genetic distance and within-host evolution were investigated based on SNPs. In total, 20 treatment failure patients and 74 patients who succeeded in treatment were included. The number of effective drugs for patients who failed treatment was no more than three. Eighteen (90.0%) treatment-failure patients were characterized by a continuous infection of the primary strain, of which 14 patients (77.8%) developed phenotypic or genotypic acquired drug resistance under ineffective treatment. Acquired resistance to amikacin and moxifloxacin (2.0 mg/ml) was detected most frequently, in 5 and 4 patients, respectively. The insufficient number of effective drugs in the combined treatment regimen was the main reason for MDR-TB treatment failure. The study emphasizes the importance of DST for second-line drugs when implementing the second-line drug regimen in MDR-TB patients. Patients with risk factors for MDR-TB, DST of second-line antituberculosis drugs should be performed at initiation of treatment. Second-line drugs should be selected based on the results of DST to avoid acquired resistance. WGS detects low-frequency resistance mutations and heterogeneous resistance with high sensitivity, which is of great significance for guiding clinical treatment and preventing acquired resistance.

IMPORTANCE  Few studies have focused on the reasons for the low cure rate of multidrug-resistant tuberculosis in China and within-host evolution during treatment, which is of great significance for improving clinical treatment regimens. Acquired resistance events were common during the ineffective treatment, among which resistance to amikacin and high-level moxifloxacin were the most common. The main reason for the treatment failure of MDR-TB patients was insufficient effective drugs, which may lead to higher levels of drug resistance in MDR-TB strains. Therefore, the study emphasizes the importance of DST in the development of second-line treatment regimen when there is a risk of MDR. By performing whole-genome sequencing of...
Drug-resistant tuberculosis (DR-TB) constitutes one of the main threats to the End-TB by 2035 strategy of the World Health Organization (WHO) (1–3). China accounts for 13% of the worldwide cases of multidrug resistant (MDR)/resistant to rifampin (RR)-TB. However, the cure rate of MDR-TB in China is as low as 41% (3). Risk factors for treatment failure include health and socioeconomic characteristics of patients, such as homelessness and anemia, as well as bacterial factors, such as infection by lineage 2 and higher resistance strains (4–11). The success rate of treatment is positively correlated with the number of effective drugs administered to patients (12, 13).

All MDR-TB patients who failed standardized treatment in accordance with the 2011 version of the WHO guidelines (14) were retrospectively analyzed in a designated TB Hospital in Zhejiang Province, China from January 2014 to September 2016 to investigate the current status and reasons for MDR-TB treatment failure. Due to the high occurrence and transmission rate of MDR-TB in China (15), it was speculated that treatment failure is likely caused by two factors: (i) a reinfection with a more resistant exogenous strain during treatment and (ii) resistance evolution of the primary strain (16–19). To distinguish between reinfection and resistance evolution, SNPs obtained by whole-genome sequencing (WGS) of strains were used to provide detailed information regarding drug resistance and its evolutionary events (20, 21). MTB infection is more genetically heterogeneous than traditionally thought (22). However, the microevolution and genetic resistance profiles acquired during treatment failure and identified on the molecular level by WGS have been even less studied.

We elucidated the current reality and the factors influencing treatment failure of MDR-TB in China and used WGS to further investigate the molecular evolution of strains during treatment failure, which has been less explored (19). These findings might reveal the current status of DR-TB treatment, which is crucial for improving future treatment strategies.

RESULTS

Basic information and DST profiles of baseline strains. In total, 123 MDR-TB patients were diagnosed between January 2014 and September 2016. Among these, 94 patients had treatment outcomes by December 2018, of which 20 were treatment failure and 74 cured. We successfully revived 94 baseline strains from the 94 patients and 40 serial strains from the 20 treatment-failure patients (Fig. 1).

The characteristics of patients, such as history of TB treatment with or without second-line anti-TB drugs and previous treatment duration of over 1 year, were associated with poor treatment outcomes (Table S1 in the supplemental material). The higher resistance level of baseline strains (especially extensively drug resistant [XDR], which means resistant to both SLID [second-line injectable drug] and FQ [fluoroquinolone], or pre-XDR, which means resistant to either SLID or FQ, resistance to FQ or to pyrazinamide [PZA]) was also associated with poor treatment outcomes (Table 1).

Importantly, insufficient administration of effective drugs was associated with poor clinical outcomes. In contrast, treatment regimens using specific effective drugs, such as PZA, levofloxacin (LFX), moxifloxacin (MFX), and prothionamide (PTO), were associated with successful outcomes (Table 1). We calculated the number of effective drugs by comparing the baseline DST and the initial treatment regimen. As the number of effective drugs decreased from $\geq 4$, to 3, to $\leq 2$ in the regimen of patients, treatment
failure was observed to increase stepwise from 0% (0/58), to 48.1% (13/27), and to 77.8% (7/9), respectively (P < 0.001; relative risk [RR], 0.04, 95% confidence interval [CI] 0.01 to 0.18). Further analysis revealed no significant differences in the drug resistance profile or effective use of specific drugs in 27 patients treated with three effective drugs; however, any history of TB treatment with or without second-line anti-TB drugs was associated with treatment failure.

**Primary infection strain or reinfection distinguished by WGS.** As reinfection by another higher-resistance MDR strain was considered a plausible reason for treatment failure, we used WGS to distinguish between primary infection and reinfection of 20 patients with poor treatment outcome. The number of different SNPs between the serial strains was in the range of 0 to 1,143. Eighteen (90.0%) cases were identified as the same strains, of which the number of SNP differences varied from 0 to 8 in this study. Only two cases (10%) were identified as reinfection by another, more resistant strain (no. 6 and no. 16), which had 1,134 and 313 SNPs in genetic distance, respectively (Fig. 2, Fig. S1 in the supplemental material).

Among the 18 cases infected with the same strain during the whole period of treatment, a total of 14 patients (77.8%) were observed to develop phenotypic or genotypic acquired drug resistance (ADR) (Table 2). The ADR events of FQ (both MFX 2.0 mg/ml and LFX) and second-line injectable drugs (SLID) were the most frequent, and were found in six (33.3%) and five (27.8%) out of 18 patients, respectively. The evolution from being drug susceptible to resistant was consistent in both the phenotype and genotype in most patients, except for the PTO phenotypic resistance of patient no. 4 and the cycloserine (CS) phenotypic resistance of patient no. 14, in which cases no mutations responsible for the acquired resistance were detected.

As no resistance-related mutation was discovered in the PTO-resistant isolate from patient no. 4 and the CS phenotypic resistance of patient no. 14, we further analyzed all differential SNPs identified between the serial isolates of these two patients. After excluding synonymous mutations, three mutations were identified to distinguish the resistant from the susceptible isolates of patient no. 14. These were Rv0565c Y306C (probable monooxygenase), Rne N649D (RNase E), and Rv2611c I102M (probable acyltransferase). Only two mutations were detected in the intergenic region of the isolate of patient no. 4, located in the promoter of mprA (mycobacterial persistence regulator)
protein) and amount genes (ammonium-transport integral membrane protein). These results provided a new insight into the acquired resistance of TB strains to drugs.

Microevolution of resistance genes revealed by whole-genome sequencing.

Here, the evolution of resistance-related genes included the identification of the pncA mutation related to PZA (patients no. 2 and no. 13), the gyrA and gyrB mutations related to FQ (patients no. 3, no. 9, no. 10, no. 13, no. 17, and no. 19), the rrs mutation related to SLID (patients no. 3, no. 5, no. 11, no. 14, and no. 18), the embB mutation related to EMB (patients no. 8 and no. 20), the alr mutation related to CS (patients no. 8 and no. 14), and the ethA mutation related to PTO (patients no. 4, no. 8, and no. 17) (Table 2). Moreover, heterogeneous resistance, indicating the coexistence of either both drug-resistant and sensitive subpopulations or several drug-resistant subpopulations with different gene mutations, was found in 8 out of 14 patients. An ongoing change in the frequency of resistance mutations was detected by WGS in a series of isolates from nine patients (patients no. 2, 3, 5, 7, 8, 9, 11, 17, and 19), indicating the process of emergence or substitution of resistant subpopulations (Fig. 2, Table 3).

In patients no. 8, no. 11, and no. 19, the emergence, selection, and fixation process of a drug resistance-related mutation were entirely recorded by WGS. In detail, the frequency of ethA W116C of patient no. 8, rrs a1401g of patient no. 11, and gyrB A504V of patient no. 19 increased from 0% at the initiation of treatment to nearly 100% in the last cultured isolates.

Interestingly, we found a mutation shift from a low-level resistance mutation to a different high-level resistance mutation. In patient no. 3, the gyrA D94N mutation, usually characterized by high level of resistance to FQ, gradually replaced the existing A90V mutation.

### Table 1: Treatment outcomes in relation to resistance patterns of baseline strains and administration of effective drugs

| Parameter                                         | Successful outcomes (no. [%]) | Poor outcomes (no. [%]) | P value<sup>b</sup> | Risk ratio (95% CI) for treatment success<sup>b</sup> |
|---------------------------------------------------|-------------------------------|-------------------------|---------------------|------------------------------------------------------|
| Resistance Pattern of baseline strains            |                               |                         |                     |                                                      |
| MDR                                               | 40 (54.1)                     | 2 (10.0)                | <0.001              | 0.13 (0.04–0.45)                                     |
| pre-XDR R to SLID                                 | 32 (43.2)                     | 1 (5.0)                 |                     |                                                      |
| pre-XDR R to FQ                                   | 1 (1.4)                       | 15 (75.0)               |                     |                                                      |
| XDR                                               | 1 (1.4)                       | 2 (10.0)                |                     |                                                      |
| Resistance to individual drugs                    |                               |                         |                     |                                                      |
| EMB                                               | 41 (55.4)                     | 15 (75.0)               | 0.113               | 0.84 (0.69–1.03)                                     |
| PZA                                               | 34 (45.9)                     | 17 (85.0)               | **0.002**           | **0.72 (0.58–0.89)**                                 |
| LFX                                               | 33 (44.6)                     | 17 (85.0)               | **0.001**           | **0.71 (0.57–0.88)**                                 |
| MFX                                               | 11 (14.9)                     | 10 (50.0)               | **0.002**           | **0.61 (0.40–0.92)**                                 |
| SLID                                              | 2 (2.7)                       | 3 (15.0)                | 0.107               | 0.49 (0.17–1.45)                                     |
| SM                                                | 49 (66.2)                     | 14 (70.0)               | 0.749               | 0.96 (0.78–1.20)                                     |
| PTO                                               | 10 (13.5)                     | 8 (40.0)                | 0.019               | 0.66 (0.43–1.01)                                     |
| PAS                                               | 6 (8.1)                       | 2 (10.0)                | 0.792               | 0.95 (0.63–1.44)                                     |
| CS                                                | 3 (4.1)                       | 6 (30.0)                | 0.002               | 0.40 (0.16–1.01)                                     |
| No. of effective drugs in patient’s treatment     |                               |                         | **<0.001**          | **0.04 (0.01–0.18)**                                 |
| 0–1                                               | 0 (0.0)                       | 1 (5.0)                 |                     |                                                      |
| 2                                                 | 2 (2.7)                       | 6 (30.0)                |                     |                                                      |
| 3                                                 | 14 (18.9)                     | 13 (65.0)               |                     |                                                      |
| ≥4                                                | 58 (78.4)                     | 0 (0.0)                 |                     |                                                      |
| Effectiveness of specific drugs                   |                               |                         |                     |                                                      |
| EMB                                               | 12 (16.2)                     | 1 (5.0)                 | 0.452               | 1.17 (0.97–1.41)                                     |
| PZA                                               | 41 (55.4)                     | 3 (15.0)                | **<0.001**          | **1.41 (1.14–1.75)**                                 |
| FQ                                                | 25 (33.8)                     | 5 (25.0)                | **<0.001**          | **1.68 (1.22–2.32)**                                 |
| SLID                                              | 71 (96.0)                     | 17 (85.0)               | 0.207               | 1.61 (0.72–3.62)                                     |
| SM                                                | 0 (0)                         | 0 (0.0)                 | /                   |                                                      |
| PTO                                               | 62 (83.8)                     | 9 (45.0)                | **0.001**           | **1.67 (1.12–2.50)**                                 |
| PAS                                               | 10 (13.5)                     | 4 (20.0)                | 0.712               | 0.89 (0.63–1.27)                                     |
| CS                                                | 49 (66.2)                     | 10 (50.0)               | 0.183               | 1.16 (0.92–1.48)                                     |
| CFZ                                               | 4 (5.4)                       | 5 (25.0)                | 0.027               | 0.54 (0.26–1.13)                                     |

a MDR, multidrug resistant; XDR, extensively drug resistant; SLID, second-line injectable drug; FQ, fluoroquinolone; EMB, ethambutol; PZA, pyrazinamide; LFX, levofloxacin; MFX, moxifloxacin; SM, streptomycin; PTO, prothionamide; PAS, para-aminosalicylic acid; CS, cycloserine; CFZ, clofazimine; /, not applicable.

b P value and risk ratio (95% CI) values given in boldface indicate statistical significance.
FIG 2 Evolution of drug resistance and treatment regimen for each patient. Different colors represent corresponding drugs. Solid circles represent resistance; hollow circle represents sensitivity. Gray lines under each patient show the treatment regimen and any changes to it. Letters in gray indicate ineffective use of this drug. Letters in bold with an asterisk indicate acquired resistance to this drug. E, ethambutol; Z, pyrazinamide; L, levofloxacin; M, moxifloxacin; A, amikacin; C, capreomycin; T, prothionamide; P, para-aminosalicylic acid; S, cycloserine; and F, clofazimine.

MDR
Pre-XDR
XDR
EMB (embA, embB, embC, ubiA)
PZA (pncA, pncA_p, pncD, rpsA)
FQs (gyrA, gyrB)
SLIDs (rrs, rps_p, rrl4)
SM (rrs, rpsL, gidB)
PTO (inhA_p, ethA)
CS (alr, ald)
PAS (fopC, dfrA, thyA, thyX, ribD)
CFZ (rv0678)
Genetic but not phenotypic resistance
Phenotypic resistance with heterogeneous mutation

WGS of Serial Treatment Failure Tuberculosis Strains
mutation, resulting in low level of resistance to FQ. This phenomenon was also observed in isolates from patient no. 10, in which the \textit{gyrA}\textsubscript{D94G} mutation was demonstrated to have replaced the previous \textit{A90V} mutation during treatment containing MFX (Table 2, Table 3).

In patients no. 5, 7, 9, and 17, several different drug-resistant subpopulations were coexisting. In patient no. 5, two mutations in the \textit{ethA} gene were found at the start of treatment, \textit{ethA}\textsubscript{S57P} and \textit{ethA}\textsubscript{Y461stop}, with frequencies of 54.9% and 34.9%, respectively.

### Table 2: Phenotypic or genotypic acquired resistance in patients of poor outcomes

| Patient no. | Acquired phenotypic drug resistance\textsuperscript{a} | Acquired genotypic drug resistance\textsuperscript{a} | Genetic drug resistance consistent with phenotype\textsuperscript{b} | Other mutations in drug resistance related genes\textsuperscript{b} |
|-------------|-----------------------------------------------------|---------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| 1           | /                                                   | /                                                 | /                                              | /                                              |
| 2           | PZA                                                 | PZA                                               | \textit{pncA}\textsubscript{L85R*}, \textit{pncA}\textsubscript{166c_in*} | /                                              |
| 3           | MFX2.0, SLID                                        | FQ, SLID                                          | \textit{gyrA}\textsubscript{A90V}→D94N, \textit{rrs}\textsubscript{a1401g} | /                                              |
| 4           | PTO                                                 | /                                                 | /                                              | /                                              |
| 5           | SLID                                                | SLID                                              | \textit{rrs}\textsubscript{a1401g}            | \textit{ethA}\textsubscript{S57P*}, \textit{ethA}\textsubscript{Y461stop*} |
| 7           | /                                                   | /                                                 | /                                              | /                                              |
| 8           | EMB, PTO, CS                                        | EMB, PTO, CS                                      | \textit{embB} M306V; \textit{ethA}\textsubscript{W116C*}; \textit{alr}\textsubscript{c-13gL113R,Y388D*} | \textit{gyrB}\textsubscript{T500A}; \textit{pncA}\textsubscript{D8A*}, \textit{pncA}\textsubscript{T1425*} |
| 9           | MFX2.0                                              | FQ                                                | \textit{gyrB}\textsubscript{ES501D*}          | /                                              |
| 10          | MFX2.0                                              | FQ                                                | \textit{gyrA}\textsubscript{A90V}→D94G        | /                                              |
| 11          | SLID                                                | SLID                                              | \textit{rrs}\textsubscript{a1401g*}          | /                                              |
| 12          | /                                                   | /                                                 | /                                              | /                                              |
| 13          | FQ, PZA                                             | FQ, PZA                                           | \textit{gyrA}\textsubscript{D94Y}, \textit{pncA}\textsubscript{T153P} | /                                              |
| 14          | SLID, CS                                            | SLID                                              | \textit{rrs}\textsubscript{a1401g}          | /                                              |
| 15          | /                                                   | /                                                 | /                                              | /                                              |
| 17          | FQ, PTO                                             | FQ, PTO                                           | \textit{gyrA}\textsubscript{D94N}; \textit{ethA}\textsubscript{F48V*}, \textit{ethA}\textsubscript{694tc_in*} | /                                              |
| 18          | SLID                                                | SLID                                              | \textit{rrs}\textsubscript{a1401g}          | /                                              |
| 19          | MFX2.0                                              | FQ                                                | \textit{gyrB}\textsubscript{A504V*}          | /                                              |
| 20          | /                                                   | /                                                 | /                                              | \textit{embB}\textsubscript{Q497H}, \textit{gyrB}\textsubscript{D461N} |

\textsuperscript{a}Boldface type indicates the genetic mutation responsible for resistance was not found. SLID, second-line injectable drug; FQ, fluoroquinolone; EMB, ethambutol; PZA, pyrazinamide; LFX, levofloxacin; MFX, moxifloxacin; PTO, prothionamide; CS, cycloserine; /, not applicable.

\textsuperscript{b}, hetero-resistance.

### Table 3: Mutation frequencies changing gradually for resistance-related mutations as detected by WGS

| Patient no. | Acquired phenotypic drug resistance\textsuperscript{a} | Acquired genetic drug resistance | Resistant mutations | Frequency of resistant mutations |
|-------------|-----------------------------------------------------|---------------------------------|---------------------|---------------------------------|
| 2           | PZA                                                 | \textit{pncA}                  | L85R, 166c_in       | 0 / 15.5 \_ \_\_ 0\
| 3           | MFX2.0                                              | \textit{gyrA}                  | A90V, D94N          | 0 / 81.7 \_ \_\_ 84.6\
| 5           | /                                                   | \textit{ethA}                  | S57P, Y461stop      | 34.9 \_ \_\_ 99.6\
| 7           | /                                                   | \textit{ethA}                  | S183R, Q254P        | 42.1 \_ \_\_ 0 \_ \_\_ 0 / 59.9 \_ \_\_ 0 / \_ \_\_ 0 / Y286stop 34.3 \_ \_\_ 23.6 \_ \_\_ 99.8 / 99.8\
| 8           | CS                                                  | \textit{alr}                   | c-13g                | 0 \_ \_\_ 0 \_ \_\_ 83.6\
| 9           | MFX2.0                                              | \textit{ethA}                  | W116C, D94H, E501V  | 0 \_ \_\_ 0 \_ \_\_ 22.8 \_ \_\_ 0 / 0 \_ \_\_ 24.3 \_ \_\_ 47.1 \_ \_\_ 29.6 / 48.7 \_ \_\_ 51.3\
| 11          | SLID                                                | \textit{rrs}                   | a1401g, E501D       | 0 \_ \_\_ 79.5 \_ \_\_ 99.7\
| 17          | PTO                                                 | \textit{ethA}                  | F48V, 694tc_in      | 0 \_ \_\_ 88.7 \_ \_\_ 28.2 \_ \_\_ 82.4\
| 19          | MFX2.0                                              | \textit{gyrB}                  | A504V               | 0 \_ \_\_ 24.8 \_ \_\_ 86.0|

\textsuperscript{a}SLID, second-line injectable drug; PZA, pyrazinamide; MFX, moxifloxacin; PTO, prothionamide; CS, cycloserine; /, not applicable.
tively. In the second (6 months later) and third (23 months later) specimens, only the ethA S57P or ethA Y461* mutations were present (Table 3). Similarly, in patient 7, three different subpopulations with drug resistance mutations of ethA were gradually fixed to carry ethA Y286* as the only mutation during ineffective treatment with PTO. The strain of patient no. 17 was initially sensitive to PTO, exhibiting a wild-type ethA. After 6 months of ineffective treatment, ethA F48V and ethA 694t-insertion mutations were both detected with frequencies of 88.7% and 10.9%, respectively. After another 16 months of continued treatment, the subpopulation carrying the ethA 694t-insertion became the majority, with its proportion rising to 82.4%, whereas the proportion of the subpopulation carrying the ethA F48V mutation decreased to 20.9%.

DISCUSSION

The WGS method is widely used in distinguishing relapse from exogenous reinfection in cases of recurrence after treatment completion, revealing that about 60% are relapse and 40% are reinfection (10, 20, 23–25). However, few studies have investigated this issue in MDR-TB treatment failure patients, who were hard to treat and remained a source of infection during unsuccessful treatment. The majority of paired strains (18/20, 90.0%) persisted genetically unchanged (SNPs #8), consistent with previous studies by WGS (21, 26), but higher than previous studies in which the genotype was defined by mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR) (18, 27, 28). The reason for the lower frequency of reinfection could be that small changes in MIRU-VNTR can make closely related strains appear very different, but the higher resolution WGS method can distinguish that these strains are actually very similar. Since the study was conducted in Wenzhou City, Zhejiang Province, there could be fewer transmission incidents in this city than in the communities sampled in other studies (21, 29).

Deep analysis of the failure cases might lead to a road of better treatment options for MDR-TB. Here, administration of an insufficient number of effective drugs was strongly associated with treatment failure and acquired drug resistance events, strengthening the previous results defining the genotype by MIRU-VNTR (13). We performed a comprehensive and standardized DST for all second-line antituberculosis drugs available at that time, remedying the limitation that previous studies did not include DST results for PZA, MFX, and PTO. Another strength of this study was that WGS-based mutations were also analyzed to confirm the acquired phenotypic resistance, highlighting the importance of DST in the treatment of DR-TB (17, 30).

In total, among patients persistently infected with the same strain, 77.8% patients (14/18) were noted to develop acquired drug resistance, which was higher than that reported previously. A previous study only performed DST of FQ and SLID at the initiation and checkpoint of treatment to determine the resistance pattern, which might have underestimated the prevalence of acquired resistance to other drugs (13, 28). The acquired resistance to FQ is the most common evolutionary event in the duration of MDR-TB treatment (13). However, in this study, as 83.8% (15/18) patients were initially resistant to FQ (resistance to either LFX or MFX), we did not focus much on the evolution event of the resistance to FQ. Acquired resistance to SLID and higher resistance level to MFX (from 0.5 mg/ml to 2.0 mg/ml) was the most frequent event and detected in five and four patients, respectively, followed by the acquired resistance to LFX (from sensitivity to resistance), PZA, PTO, CS, and ethambutol (EMB) found in two patients.

Our study reemphasized the importance of the usage of FQ in treatment (31), as the success rate of treatment was significantly higher in FQ-S patients effectively treated with FQ, in accordance with previously reported conclusions (32, 33). The usage of MFX to treat LFX-resistant MDR-TB patients, regardless of the effectiveness of the treatment combination, resulted in the evolution of a higher level of resistance to FQ (34), a finding that merits serious attention. In patients no. 3 and no. 10, the originally identified gyrA A90V resistance mutation (low level) was replaced by mutations with higher levels of resistance, gyrA D94N and D94G (35). Accordingly, in patients no.
Heterogeneous drug resistance is a common reason for discordant results in pheno-
typic and genotypic DSTs. The coexistence of subpopulations with different drug re-
sistance profiles in the same patient might result in unfavorable responses to treat-
ment, and might lead to treatment failure (36–39). Accordingly, we noted the
simultaneous coexistence of multiple subpopulations containing different drug-resistant
mutations in the early isolates of patients no. 3, 5, 7, and 17. After a period of drug
pressure screening, a single subpopulation began to dominate, and in some cases
became the sole population, with the mutation reaching 100% frequency, suggesting
that the selection of TB resistance is common under long-term infection and drug pres-
sure (39–42). Hence, these highly resistant and relatively fit TB bacteria might be involved
in the spread from the early steps of infection (43). These findings underscore the impor-
tance of early detection of resistance, especially the detection of the resistant subpopula-
tions before and during the treatment of DR-TB. As a highly sensitive molecular detection
method, WGS could be used to diagnose these drug-resistant subgroups early, thereby
reducing the possibility of being screened as fully drug-resistant infections in the future.

Most cases of phenootypic drug resistance can be explained by mutations in drug re-
sistance-related genes. However, no corresponding molecular resistance mutations were
found in two of these strains, resistance to PTO in patient no. 4 and resistance to CS in
patient no. 14. We targeted a few SNPs during the microevolution of these resistance
cases, which requires subsequent in vitro validation and screening in a larger population.

This study had the following limitations. First, the treatment regimen was based on
the 2011 version of the WHO guidelines, what was available and used at that time. The
order of recommendation for the administration of some of the drugs has since
changed. As a retrospective study, DSTs could not be provided to the clinic in a timely
manner. Second, any compliance issues of patients and loss of follow-up were ignored.
Third, due to the procedure of revival of sputum specimens and the decontamination
operations involved in this process, some subpopulations might have been lost and
become undetected in WGS analysis. Third, as this was a single-center study, it
included an insufficient number of MDR-TB patients. Finally, other factors that might
influence treatment outcome, such as host-pathogen interaction or socioeconomic sta-
tus, were not investigated in this study.

In this study, the main reason for the treatment failure of MDR-TB patients was
insufficient effective drugs, which may lead to higher levels of drug resistance in MDR-
TB strains. Therefore, the study emphasizes the importance of DST of second-line drugs
when implementing the second-line drug regimen in MDR-TB patients. WGS detects
low-frequency resistance mutations and emerging heterogeneous resistance with high
sensitivity, which is of great significance for guiding clinical treatment and preventing
acquired resistance.

MATERIALS AND METHODS

Clinical MDR-TB cases. We retrospectively included all MDR-TB patients from January 2014 to
September 2016 in the Wenzhou Central Hospital (Zhejiang Province, China) with a known outcome accord-
ing to the standard outcome definitions by WHO (3). DST of first-line antituberculosis agents (isoniazid [INH]
and rifampin [RIF]) was conducted routinely on positive cultures by MGIT 960 to determine whether it was
MDR. Patients were divided into two groups according to the treatment outcome: treatment success and
treatment failure. The treatment-success group included patients who had been either cured or had com-
pleted treatment. The treatment-failure group included patients exhibiting lack of conversion by the end of
the intensive phase or bacteriological reversion in the continuation phase after conversion to negative. As
these patients received treatment from 2014 to 2016, the WHO guidelines for the programmatic manage-
ment of the drug-resistant tuberculosis 2011 update (14) was the only one available and used at that time.
This standardized treatment combination included the administration of pyrazinamide (PZA), a second-line
injectable drug (SLID) (amikacin [AM], kanamycin [KM], or capreomycin [CM]), a fluoroquinolone (levofloxacin
[LFX], or moxifloxacin [MFX]), and two of cycloserine (CS), prothionamide (PTO), p-aminosalicylic acid (PAS),
clofazimine (CFZ), or ethambutol (EMB) for the period of 6 to 8 months during the intense phase, continued
with administration of a combination of 3 to 4 drugs without a SLID for another 18 months.

Clinical information, including age, gender, comorbid conditions, treatment history, and treatment
regimen was extracted from the medical records of patients to analyze the risk factors related to
treatment outcomes. Baseline strains, the first sputum culture positive strain, of all enrolled patients were collected and revived from refrigeration. For all treatment failure patients, sputum specimens were collected every month for the first 6 months, and then every 1 to 2 months according to WHO guidelines. In order to observe evolution events and heterogeneity, we selected at least two more serial strains at intervals of more than 6 months. Strains that failed to revive or were contaminated were excluded. All colonies on the plate were scraped off and resuspended in 30% glycerol before freezing.

The study was approved by the Ethics Committee of Wenzhou Central Hospital, Zhejiang Province, China. All patients provided written informed consent before the study.

**Phenotypic drug susceptibility tests.** Drug susceptibility tests (DSTs) were conducted on all included strains to compare the resistance profiles between the two groups. Following the revival of strains on Löwenstein–Jensen medium, we performed DSTs for 14 drugs (44–50) on the baseline strains of all patients and the series strains of treatment failure patients, namely, INH (0.2 μg ml⁻¹), RIF (40.0 μg ml⁻¹), EMB (2.0 μg ml⁻¹), LFX (2.0 μg ml⁻¹), MFX (2.0 μg ml⁻¹), AM (30.0 μg ml⁻¹), KM (30.0 μg ml⁻¹), CM (40.0 μg ml⁻¹), streptomycin (SM) (4.0 μg ml⁻¹), PAS (1.0 μg ml⁻¹), CFZ (1.0 μg ml⁻¹), and CS (30.0 μg ml⁻¹) using the proportion method on Löwenstein–Jensen medium (Baso, Zhuhai, Guangzhou Province, China). Exceptions were for PZA (100.0 μg ml⁻¹) and PTO (2.5 μg ml⁻¹), the DSTs of which were performed using an automated MGIT 960 (Becton, Dickinson Diagnostic Systems, Franklin Lakes, NJ, USA) according to the manufacturer’s guidelines. We conducted the DSTs of EMB, PZA, and PTO at least twice due to their unsatisfactory reproducibility. Where the results were inconsistent, a third test was performed and the interpretation was based on the two most consistent results out of the total three.

**Whole-genome sequencing.** Whole-genome sequencing (WGS) was performed on all selected strains to provide genotypic resistance, distinguish between a continuous infection with the primary strain or reinfection, and elucidate the microevolution of serial strains. Growth was scraped from Löwenstein–Jensen medium. Genomic DNA was extracted using the Qiagen DNeasy blood and tissue kit (Cat. no. 69506) and sequencing libraries were constructed using the Nextera XT sample prep kit (Illumina, San Diego, CA, USA) following the manufacturer’s protocol. All strains were sequenced on an Illumina Miseq or X10 with at least 100-fold coverage.

WGS data were analyzed (51) according to previous studies. After filtering the low-quality reads, the reads were aligned to the MTB H37Rv (GenBank NC_000962.3) reference sequence using Bowtie2 (version 2.3.3.1) with default parameters. Single nucleotide polymorphisms (SNPs) were detected using SAMtools (version 1.6) with a minimum sequencing depth of 10 reads without strand bias and a frequency of no less than 10%. All SNPs with a mutation frequency exceeding 10% were retained in the step of calling SNPs to detect microevolution and minor subpopulations. If the mutation ratio of a certain site was above 80%, it was considered a fixed mutation.

SNPs in highly repetitive regions such as PE and PPE, GC-enriched sequences, and drug resistance-related genes were removed from the analysis. The phylogenetic tree was constructed using the maximum likelihood method using MEGA (version 7.0) software based on the fixed SNPs with H37Rv as the root. The strains with a genetic distance of no more than 12 SNPs were considered persistent infection with the same strain.

**Ethical approval.** The study was approved by the Ethics Committee of Wenzhou Central Hospital, Zhejiang Province, China. All patients provided written informed consent before the study.

**Statistical analysis.** We used the chi-square test or Fisher’s exact test to calculate significant differences between characteristics of patients, drug resistance, and treatment regimen and outcome. We performed univariable logistic regression analysis and calculated the relative risk (RR) followed by its 95% confidence intervals. Variables with a P < 0.05 were considered significant. We performed all analyses using the SPSS version 21 software.

**Data availability.** The raw data of WGS are submitted to the SRA database and can be accessed by the public via BioProject accession number PRJNA613359. The SRA accession numbers for these isolates are SAMN14402132 to SAMN14402172. The WGS data for a portion of these strains were previously made available to the public under BioProject number PRJNAS22942 (51).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1, DOCX file, 0.1 MB.**

**TABLE S1, DOCX file, 0.01 MB.**

**TABLE S2, DOCX file, 0.02 MB.**

**ACKNOWLEDGMENTS**

All persons meeting authorship criteria are listed as authors, and all authors certify that they have sufficiently participated in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript.

Conception and design of study, critically revising the manuscript for important intellectual content: J.C. and W.Z.; acquisition of data, analysis, and interpretation of data: X.C., G.H., S.W., S.L., and F.S.; drafting the manuscript: X.C. and J.C.

All authors declare they have no competing interests regarding the manuscript.

The work was supported in part by the National Science and Technology Major Project of China (2017ZX10302301-001), the National Natural Science Foundation of China.
REFERENCES

1. Pankhurst LJ, del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, Fernmont JM, Gascony-Binzi DM, Kohl TA, Kong C, Lemaître N, Niemann S, Paul J, Rogers TR, Roycroft E, Smith EC, Supply P, Tang P, Wilcox MH, Wordsworth S, Wyllie D, Xu L, Crook DW, COMPASS-TB Study Group. 2016. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med 4:49–58. https://doi.org/10.1016/S2213-2600(15)00466-X.

2. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GKH, Pasapanodya YJ, Rodrigues C, Clark TG, Sigel FA, Esmai A, Lin H-H, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuerenberg E, McFillerson K, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. 2017. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine 5:291–360. https://doi.org/10.1016/S2213-2600(17)30079-6.

3. World Health Organization. 2018. Global tuberculosis report. World Health Organization, Geneva, Switzerland.

4. Thai PVK, Ha DTM, Hanh NT, Day J, Dunstan S, Nhu NTQ, Kiet VS, Lan NH, Dung NH, Lan NT, Thong NT, Lan NN, Liou PT, Hong NT, Di JDP DC, Thanh NTK, Hoi NV, Nghia NV, Dai TN, Minh HQ, Thun NV, Farrar J, Caws M. 2018. Bacterial risk factors for treatment failure and relapse among drug-resistant tuberculosis. BMC Infect Dis 18:112. https://doi.org/10.1186/s12879-018-3033-9.

5. Dooley KE, Lahou O, Ghali I, Knudsen J, Ellmesauodi MD, Cherkouaoui I, El Aouad R. 2011. Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco. BMC Public Health 11:140. https://doi.org/10.1186/1471-2458-11-140.

6. Parwati I, Alisjahbana B, Apriani L, Soetikno RD, Ottenhoff TH, van der Merwe J, van Sooelingen D, van Crevel R. 2010. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis 201:553–557. https://doi.org/10.1086/650311.

7. Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC. 2017. Treatment outcomes of patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health 22:351–362. https://doi.org/10.1111/t[:]1.12879.-

8. Albana O, Bachmaha M, Krasiov I, Rybak N, Flanigan TP, Petrenko V, Murray MB. 2017. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect Dis 17:129. https://doi.org/10.1186/s12879-017-2230-2.

9. Hang NT, Maeda S, Keicho N, Thuong PH, Endo H. 2015. Emergence of Mycobacterium tuberculosis Beijing genotype strains and unfavorable outcomes of anti-tuberculosis treatment. Tuberculosis (Edinb) 95:336–342. https://doi.org/10.1016/j.tube.2015.02.040.

10. Guerra-Assuncao JA, Houben RM, Campin AC, Mzembe T, Mallard K, Coll F, Khan P, Bautista C, Pereira RP, McNerney R, Harris D, Parkhill J, Clark TG, Glynne JR. 2015. Recurrence due to re-infection or re-infection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. Infect Genet Evol 31:1154–1163. https://doi.org/10.1016/j.meegid.2015.04.026.

11. Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, Gray DJ, Clements ACA, Xu Z. 2017. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis in Hunan Province, China. BMC Infect Dis 17:573. https://doi.org/10.1186/s12879-017-2662-8.

12. Loutet MG, Davidson JA, Brown T, Dedicoat M, Thomas HL, Lalor MK. 2018. Acquired resistance to antituberculosis drugs in England, Wales, and Northern Ireland, 2000–2015. Emerg Infect Dis 24:524–533. https://doi.org/10.3201/eid2403.171362.

13. Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoli JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnowsky C, Leimane V, Kuksa L, Chen MP, Bai L, Gray DJ, Clements ACA, Santis PH, de la Fuente JA, Houben RM, van der Merwe J, van Sooelingen D, van Crevel R. 2017. Recurrent tuberculosis in an urban area in China: relapse or exogenous reinfection? Tuberculosis (Edinb) 103:97–104. https://doi.org/10.1016/j.tube.2017.01.007.

China (81761148027), and the Basic Public Welfare Research Project of Zhejiang Province (LGF20H010003). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

We are grateful for the support of the Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response (20dxz2260100).

November/December 2020 Volume 5 Issue 6 e00884-20 mSphere.asm.org 10
25. Guerra-Assunção JA, Crampin AC, Houben RM, Mzembe T, Mallard K, Coll F, Khan P, Bandala L, Chivuwa A, Pereira RP, McNerny R, Fine PE, Parkhill J, Clark TG, Glynn JR. 2015. Large-scale whole genome sequencing of M. tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. J Clin Microbiol 55:457–469. https://doi.org/10.1128/JCM.02116-16.

26. Wollenberg KR, Desjardins CA, Zalutskaya A, Slodovnikova V, Oler AJ, Quinones M, Abeel T, Chapman SB, Tartakovskiy M, Gabrielson L, Hoffner S, Skrha A, Binrey BW, Rosenthal A, Skrha A, Earl AM. 2017. Whole-genome sequencing of Mycobacterium tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus. J Clin Microbiol 55:457–469. https://doi.org/10.1128/JCM.02116-16.

27. Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, Maryandyshov AO, Shemyakin IG, Kurbatova E, Cegeijski JP. 2015. Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005–2010. Emerg Infect Dis 21:1002–1011. https://doi.org/10.3291/eid2106.141907.

28. Cegielski JP, Dalton T, Yagui M, Wattanapoomkiet W, Volchenkov GV, Via ER, Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. 2012. Acquired resistance to second-line drugs among persons with tuberculosis in the United States. Clin Infect Dis 55:1600–1607. https://doi.org/10.1093/cid/cis748.

29. Sun F, Li Y, Chen Y, Guan W, Jiang X, Wang X, Ren P, Li J, Shi J, He G, Wu M, Tang P, Wang F, Sheng Y, Huang F, Zhou Z, Huang H, Hong L, Liu Q, Zhang Y, Zhang W. 2019. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. Eur Respir J 53:1801770. https://doi.org/10.1183/13993003.01770-2018.

30. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Lee H, Ahn S, Hwang NY, Jeon K, Kwon OJ, Huh HJ, Lee NY, Kim CK, Koh Y-K, Khan P, Banda L, Chiwaya A, Pereira RP, McNerney R, Fine PE, Parkhill J, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim H-R, Koh W-J, Ko C, Copin R, Wang X, Louie E, Escuyer V, Coscilla M, Gagneux S, Palmer GH, Emf JD. 2016. Within host evolution selects for a dominant genotype of Mycobacterium tuberculosis while T cells increase pathogen genetic diversity. PLoS One 6:112147. https://doi.org/10.1371/journal.pone.012147.

31. Casali N, Nikolayevsky V, Babalovanova Y, Ignatyeva O, Kontsevaya I, Harris SR, Bentley SD, Parkhill J, Nejentsev S, Hoffner SE, Horstmann RD, Brown T, Drobniewski F. 2012. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res 22:735–745. https://doi.org/10.1101/gr.128678.111.

32. Ley SD, de Vos M, Quigmire CA, Warren AM. 2012. Novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis while T cells increase pathogen genetic diversity. PLoS Pathog 12:e1006111. https://doi.org/10.1371/journal.ppat.1006111.

33. Seraphin NM, Mann M, Rasmussen EM, Gerace AM, Chiribau CB, Rowlinson MC, Lillebaek T, Lauzardo M. 2019. Direct transmission of within-host Mycobacterium tuberculosis diversity to secondary cases can lead to variable between-host heterogeneity without de novo mutation: a genomic investigation. ElBioMedicine 47:293–300. https://doi.org/10.1016/j.elsbmed.2019.08.010.

34. Farhat MR, Shapiro B, Kiese JS, Sultana R, Jacobsson KR, Victor TC, Warren RM, Sticherl EM, Calver A, Sloutsky A, Davis PE, Pilarylak B, Oggioni MR, Galy JD, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky MS, Muddukrishna B, Kaeiwrith BN, Kurepina N, Galagan J, Gagneux S, Binrey B, Rubin EJ, Lander ES, Sabeti PC, Murray M. 2013. Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet 45:1183–1189. https://doi.org/10.1038/ng.2747.

35. World Health Organization. 2018. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. World Health Organization, Geneva, Switzerland.

36. Zhao F, Xiao WD, Erber LN, Luo M, Guo AZ, Yang SS, Gu J, Turman B, Gao YR, Li DF, Cui QZ, Zhang ZP, Bi L, Baughn AD, Zhang XE, Deng JY. 2014. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:1479–1487. https://doi.org/10.1128/AAC.01775-13.

37. Zhang Y, Liu L, Zhang Y, Dai G, Huang H, Lin Q. 2015. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012. Antimicrob Agents Chemother 59:1320–1324. https://doi.org/10.1128/AAC.03695-14.

38. Ismail N, Oma SV, Ismail NA, Peters RP. 2018. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief 20:1975–1983. https://doi.org/10.1016/j.dib.2018.09.057.

39. Hartkool RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979–2981. https://doi.org/10.1128/AAC.00373-14.

40. Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. 2015. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70:2507–2510. https://doi.org/10.1093/jac/dkv150.

41. Anonymous. 2014. WHO guidelines approved by the guidelines review committee, companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis 2014. World Health Organization, Geneva, Switzerland.

42. Chen X, He G, Wang S, Lin S, Chen J, Zhang W. 2019. Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical multi-drug resistant Mycobacterium tuberculosis isolates from China. Front Microbiol 10:1741. https://doi.org/10.3389/fmicb.2019.01741.